节点文献

利那洛肽联合聚乙二醇电解质散在肠道准备中的有效性及安全性meta分析

Efficacy and safety of linaclotide combined with polyethylene glycol electrolyte powder in bowel preparation:A meta-analysis

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 谢沁松刘露路王珏郑艳古赛

【Author】 XIE Qinsong;LIU Lulu;WANG Jue;ZHENG Yan;GU Sai;Department of Gastroenterology,the First Affiliated Hospital of Chongqing Medical University;

【通讯作者】 古赛;

【机构】 重庆医科大学附属第一医院消化内科

【摘要】 目的 系统评价利那洛肽联合聚乙二醇(PEG)电解质散在肠道准备中的有效性和安全性。方法 计算机检索PubMed、Web of Science、the Cochrane Library、Embase、中国知网、中国生物医学文献数据库、万方、维普网数据库,搜集有关利那洛肽联合PEG作为肠道准备方案的临床研究,检索时间均从建库起至2023年5月。由2位研究者独立对纳入文献进行资料提取和质量评价,使用RevMan5.4软件进行meta分析。结果 最终共纳入11篇文献,共计2 381例患者,其中利那洛肽联合PEG组1 193例,PEG组1 188例。Meta分析结果显示,利那洛肽联合PEG组波士顿肠道准备评分[平均差(MD)=-0.02,95%可信区间(95%CI)-0.10~0.07,P=0.69]、腺瘤检出率[相对危险度(RR)=0.95,95%CI 0.78~1.16,P=0.61]与PEG组相比无显著差异。在安全性方面,利那洛肽联合PEG组恶心发生率(RR=0.48,95%CI 0.39~0.58,P<0.001)、腹胀发生率(RR=0.46,95%CI 0.33~0.63,P<0.001)、腹痛发生率(RR=0.27,95%CI 0.16~0.43,P<0.001)、呕吐发生率(RR=0.32,95%CI 0.19~0.52,P<0.001)均显著低于PEG组。结论 利那洛肽联合PEG作为肠道准备方案不仅可减少PEG的用量,还可减少胃肠道不良反应的发生。

【Abstract】 Objective To systematically evaluate the efficacy and safety of linaclotide combined with polyethylene glycol(PEG) electrolyte powder in bowel preparation.Methods PubMed, Web of Science, the Cochrane Library, Embase, China National Knowledge Infrastructure(CNKI),China Biomedical Literature Database(CBM),Wanfang and VIP databases were searched by computer to collect clinical studies on linaclotide combined with PEG as a bowel preparation regimen.The search time was from the establishment of the databases to May 2023.Two researchers independently extracted data and assessed the quality of the included studies.Meta-analysis was performed using RveMan5.4 software.Results A total of 11 articles were included, with a total of 2 381 patients, including 1 193 cases in the linaclotide combined with PEG group and 1 188 cases in the PEG group.The results of meta-analysis showed that there was no significant difference in Boston bowel preparation score [mean difference(MD)=-0.02,95% confidence interval(95%CI)-0.10-0.07,P=0.69] and adenoma detection rate [relative risk(RR)=0.95,95%CI 0.78-1.16,P=0.61] between linaclotide combined with PEG group and PEG group.In terms of safety, the incidence of nausea(RR=0.48,95%CI 0.39-0.58,P<0.001),abdominal distension(RR=0.46,95%CI 0.33-0.63,P<0.001),abdominal pain(RR=0.27,95%CI 0.16-0.43,P<0.001) and vomiting(RR=0.32,95%CI 0.19-0.52,P<0.001) in the linaclotide combined with PEG group were significantly lower than those in the PEG group.Conclusion As a bowel preparation regimen, linaclotide combined with PEG can not only reduce the amount of PEG,but also reduce the incidence of gastrointestinal adverse reactions.

【关键词】 利那洛肽肠道准备meta分析有效性安全性
【Key words】 LinaclotideBowel preparationMeta-analysisEfficacySafety
  • 【文献出处】 现代医药卫生 ,Journal of Modern Medicine & Health , 编辑部邮箱 ,2023年23期
  • 【分类号】R574
  • 【下载频次】23
节点文献中: 

本文链接的文献网络图示:

本文的引文网络